Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results